Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Total Current Liabilities (2016 - 2025)

Arcadia Biosciences (RKDA) has disclosed Total Current Liabilities for 12 consecutive years, with $2.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Current Liabilities fell 1.85% year-over-year to $2.3 million, compared with a TTM value of $2.3 million through Sep 2025, down 1.85%, and an annual FY2024 reading of $2.6 million, down 28.61% over the prior year.
  • Total Current Liabilities was $2.3 million for Q3 2025 at Arcadia Biosciences, up from $1.8 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $7.7 million in Q2 2021 and bottomed at $1.8 million in Q2 2025.
  • Average Total Current Liabilities over 5 years is $4.0 million, with a median of $4.1 million recorded in 2022.
  • The sharpest move saw Total Current Liabilities tumbled 40.08% in 2024, then dropped 1.85% in 2025.
  • Year by year, Total Current Liabilities stood at $5.0 million in 2021, then fell by 16.49% to $4.2 million in 2022, then dropped by 14.71% to $3.6 million in 2023, then dropped by 28.61% to $2.6 million in 2024, then decreased by 10.85% to $2.3 million in 2025.
  • Business Quant data shows Total Current Liabilities for RKDA at $2.3 million in Q3 2025, $1.8 million in Q2 2025, and $2.2 million in Q1 2025.